| Followers | 71 |
| Posts | 9002 |
| Boards Moderated | 0 |
| Alias Born | 03/06/2016 |
Wednesday, July 16, 2025 10:56:56 PM
So yes I believe the MAA was submitted for glioblastoma. But the structure of the label may have evolved during review to match how the product is already being used.
Since you appear to be a reasonable person and have a command/understanding of the complications of the application, let me ask you a few questions...
1) Do you believe the approval decision on DCVax-L, will be more than glioblastoma?
2) Do you believe approval will also include EDEN as the go to for manufacturing?
3) Do you sense news, on the franchisee(s), will be announced shorty after approval (within 2 weeks)?
I realize no one knows for sure, however, I am curious on what you think, since I believe much of the delay is due to fact that the MHRA opened up a "can of worms" when they began reviewing the Specials data. I also believe, that is why we had 2 acceptance dates (January for glioblastoma and March for the Special's data). This may also explain why there were 1.7m pages. An extreme amount of information to digest and understand...And once the MHRA dug deep, they realized they needed guidelines on RWD because of the Special data and needed SI 2025 No. 87 to become effective to allow EDEN to move forward. I understand that many will say impossible because the company never updated, however, they did say they will not comment on anything until a decision is made. Lots of moving parts. A very dynamic situation. If all true, it would make sense to remain silent until the final verdict. Lots of "what ifs" so best to remain silent until D-Day.
If it is easier for you to apply a percentage, versus a yes or no, that will be okay.
Final note: It is difficult for me to comprehend this long delay without some far reaching moves. People are dying and perhaps the delay may resulted in people not being able to utilizing the treatment straight away, however, expanding the treatment and/or increasing the number of patients to be treated may in the long run save many others. I am at a loss, in seeing the delay in any other way.
Thank you for your input. Greatly appreciated.
Recent NWBO News
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 04/21/2026 04:15:08 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 04/16/2026 09:25:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
